Literature DB >> 15302850

Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts.

Jaewoo Lee1, Sheila N Sait, Meir Wetzler.   

Abstract

We asked herein whether functional dendritic-like cells could be generated from t(9;22) acute lymphoblastic leukemia (ALL) blasts. We first determined that the combination of interleukin (IL)-1beta, IL-3, IL-7, tumor necrosis factor-alpha, stem cell factor and CD40 ligand was optimal for generating dendritic-like cells from t(9;22) ALL cell lines. Following 6 days in culture, four of five cell lines demonstrated dendrite-like morphology, upregulation of CCR7, CD54, CD80 and CD86, uptake of extracellular proteins and activation of T cells, and similar results were obtained with blasts from three t(9;22) ALL patients. The dendritic-like cells appeared to be composed of populations resembling both immature and mature dendritic cells (DCs), distinguished by CD80 expression. CD80-CD86+ cells were classified as immature DCs, demonstrating high endocytic capability and inducing minimal allogeneic T cell proliferation, while CD80+CD86+ cells were classified as mature DCs, exhibiting negligible endocytic capability and inducing robust allogeneic T cell proliferation. These mature dendritic-like cells induced autologous cytotoxic T cell responses against the unmodified blasts in a patient who achieved prolonged remission. In summary, CD80+CD86+ cells generated from t(9;22) ALL blasts may be useful in adoptive immunotherapy for t(9;22) ALL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302850     DOI: 10.1093/intimm/dxh139

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function.

Authors:  Michael T Brady; Austin Miller; Sheila N Sait; Laurie A Ford; Hans Minderman; Eunice S Wang; Kelvin P Lee; Heinz Baumann; Meir Wetzler
Journal:  Leuk Res       Date:  2013-04-28       Impact factor: 3.156

2.  Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells.

Authors:  Michael T Brady; Jaewoo Lee; Soldano Ferrone; Eunice S Wang; Meir Wetzler
Journal:  Leuk Res       Date:  2010-10-12       Impact factor: 3.156

3.  Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia.

Authors:  Norma J Nowak; Sheila N J Sait; Amer Zeidan; George Deeb; Dan Gaile; Song Liu; LaurieAnn Ford; Paul K Wallace; Eunice S Wang; Meir Wetzler
Journal:  Cancer Genet Cytogenet       Date:  2010-05

4.  Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies.

Authors:  Allison S Drake; Michael T Brady; Xin Hui Wang; Sheila J N Sait; Justin C Earp; Sampa Ghoshal Gupta; Soldano Ferrone; Eunice S Wang; Meir Wetzler
Journal:  Cancer Immunol Immunother       Date:  2008-08-02       Impact factor: 6.968

Review 5.  Immunotherapy in acute leukemia.

Authors:  Wing Leung
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

6.  CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations.

Authors:  Jawad Francis; Avinash V Dharmadhikari; Sheila N J Sait; George Deeb; Paul K Wallace; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Leuk Lymphoma       Date:  2013-01-03

7.  Photo/thermo-responsive and size-switchable nanoparticles for chemo-photothermal therapy against orthotopic breast cancer.

Authors:  Ying Bi; Miao Wang; Lirong Peng; Lifo Ruan; Mengxue Zhou; Yi Hu; Jun Chen; Jimin Gao
Journal:  Nanoscale Adv       Date:  2019-12-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.